Reference : Less vasoocclusive disease after intravenous ersus oral busulfan for autologous hematopo...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/119859
Less vasoocclusive disease after intravenous ersus oral busulfan for autologous hematopoietic cell transplantation : the Belgian pediatric experience
English
Huybrechts, S. [> >]
BEGUIN, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Ferster, A. [> >]
Laureys, G. [> >]
Uyttebroeck, A. [> >]
Vermeylen, C. [> >]
2012
Belgian Journal of Hematology
Ariez Medical Publishing
3
2
34-40
Yes
International
Amsterdam
The Netherlands
[en] autologous hematopoietic stem cell transplantation ; intravenous and oral busulfan ; combined regime ; children ; solid tumours ; veno-occlusive disease
[en] Busulfan is commonly used in preparative conditioning regimens prior to hematopoietic stem cell transplantation in children and young adults for malignant and non-malignant disorders. For many years Busulfan was only available in an oral form, resulting in large inter- and intra-patients variability in plasma exposure, associated with higher graft failure rate as well as higher toxicity such as venoocclusive disease. With the development of an intravenous formulation of Busulfan, a more accurate control of both the inter- and intra-patient variability has been provided. The goal of this study was to evaluate the use and efficacy of intravenous Busulfan in comparison with the oral formulation in children undergoing an autologous transplantation after conditioning with Busulfan. Despite the small number of patients, this study confirmed the apparent benefit of intravenous Busulfan in children undergoing an autologous HSCT. The use of a 5-level dose schedule defined by body weight resulted in an efficient engraftment with marked reduction in the incidence of veno-occlusive disease compared with oral Bu. In terms of diseasefree outcome, survival and event-free survival, similar results have been obtained in
both groups. The choice of this formulation of Busulfan should therefore be considered.
http://hdl.handle.net/2268/119859

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
283.pdfPublisher postprint413.2 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.